Venus Remedies Q1 FY27: net profit up 139% to ₹22.97 crore, revenue up 36%
Venus Remedies (BSE: VENUSREM) said it has published its Q1 FY27 results (consolidated), reporting revenue of ₹179 crore (+35.6% year on year), net profit of ₹22.97 crore (+139.3%), earnings per share of ₹17.18. The company is valued at about ₹1,954 crore.
What happened
Venus Remedies (BSE: VENUSREM) informed the stock exchanges on 26 October 2026 at 06:31 PM that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹179 crore (+35.6% year on year), net profit of ₹22.97 crore (+139.3%), earnings per share of ₹17.18.
From the filing: "Outcome of Board Meeting date 26th October 2026 and Unaudited Financial Results for the period ended on 30th September 2026."
Company snapshot
Venus Remedies is a small-cap company, with a market value of about ₹1,954 crore.
The stock last traded at ₹1,461.8, against a 52-week range of ₹432.1–₹2,044.3 (28.5% below the high).
Before this filing the shares had moved −12.9% over the month and −15.2% over three months. Average daily turnover over the last 20 sessions was about ₹5.75 crore.
Promoters held 41.76% at the end of Q1 FY27. Foreign institutions owned 2.92% and domestic institutions 0.89%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 132 | 9.6 | 7.18 |
| Q2 FY26 | 193 | 20.1 | 15.06 |
| Q3 FY26 | 180 | 25.6 | 19.14 |
| Q4 FY26 | 259 | 47.5 | 35.53 |
| Q1 FY27 | 179 | 23 | 17.18 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
Market-wide, 9,745 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 26 October 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Venus Remedies receives five marketing approvals In Kazakhstan, Peru, Kuwait, Argentina
- Venus Remedies secures 5 marketing authorisations in 4 global markets
- Venus Remedies Secured Five Marketing Authorisations Across Kazakhstan, Peru, Kuwait And Argentina
- Venus Remedies (VENUSREM.NS) Slips 0.71% to ₹1,574.30, Holding Above ₹1,495 Support Zone - Volatility Breakout Picks
- Is Venus Remedies the Best Stock in Its Sector? A Look at the Numbers
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.